Shulou(Shulou.com)11/24 Report--

CTOnews.com November 25 news, Qinshan nuclear power said that it has joined Shanghai nuclear engineering research and design institute, national nuclear zirconium industry co., ltd., nuclear north nuclear fuel element co., ltd., zhejiang yi nuclear medical technology co., ltd. held yttrium-90 glass microsphere target development start-up (video) meeting, deployment yttrium-90 glass microsphere target development and supporting research and development work.

The research and development of yttrium-90 glass microsphere target is one of the major projects in the construction of Qinshan nuclear power isotope production base, which is the first attempt to produce yttrium-90 glass microsphere by commercial reactor in the world. After the project is put into production, it will give full play to the advantages of long-term stable high-power operation of commercial reactors, ensure stable supply of yttrium-90 microspheres, and bring good news to liver cancer patients. The project team will actively complete the development of target parts and related work, and make every effort to ensure that the first batch of products will be released from the reactor by 2023.

Qinshan Nuclear Power has clearly established isotope production bases, further promoted the application of nuclear technologies such as isotope production, made every effort to build a national demonstration base for nuclear technology application industries, and actively promoted the development of isotope application industry chains. CTOnews.com learned that Qinshan Nuclear Power has achieved mass production of cobalt-60 and carbon-14 isotopes, and is actively promoting the research and development of strontium-89 and other medical isotopes.

extended reading

Yttrium-90 glass microspheres are mainly used to treat liver cancer. It is understood that primary liver cancer is the sixth most common malignant tumor in the world, and death ranks fourth. Less than 20% of patients can undergo surgery. China is a big country with liver cancer, accounting for more than half of the world's cases.

Yttrium-90 microsphere advanced liver cancer specific drugs have been marketed in the United States, Europe and other regions for many years, and have been treated more than 100,000 times in more than 50 countries, which can significantly prolong the survival time of patients and significantly improve the quality of life of patients. In September 2021, China carried out the first licensed yttrium-90 resin microsphere treatment liver cancer surgery, and then combined with other treatment methods, finally cured the patient.

On January 30,2022, with the approval of clinical trial or marketing of yttrium-90 radioactive microspheres by the state, yttrium-90 glass microspheres and yttrium-90 resin microspheres were gradually applied to clinical practice in mainland China. More and more patients with liver malignant tumors all over the country received yttrium-90 precise interventional surgery and achieved remarkable curative effect. The treatment of liver cancer in China entered the era of "yttrium."

Welcome to subscribe "Shulou Technology Information " to get latest news, interesting things and hot topics in the IT industry, and controls the hottest and latest Internet news, technology news and IT industry trends.